Marina Baretti

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. Epigenomics 74%
3. Adenocarcinoma 66%
4. Neoplasms 61%
5. Microsatellite Instability 38%
6. Nivolumab 35%
7. Progression-Free Survival 35%
8. Survival 34%
9. Therapeutics 32%
10. Mutation 32%
11. Tumor Microenvironment 30%
12. Hepatocellular Carcinoma 30%
13. Recurrence 28%
14. Liver Neoplasms 28%
15. Fibrolamellar hepatocellular carcinoma 26%
16. Liver 26%
17. Neoplasm Metastasis 26%
18. Biomarkers 26%
19. pembrolizumab 25%
20. DNA Mismatch Repair 24%
21. Immunotherapy 24%
22. Azacitidine 24%
23. Biliary Tract Neoplasms 24%
24. Physicians' Practice Patterns 23%
25. Circulating Tumor DNA 22%
26. Epigenome 22%
27. Neuroendocrine Carcinoma 20%
28. Tumor-Infiltrating Lymphocytes 19%
29. Epirubicin 19%
30. Adjuvant Chemotherapy 19%
31. Cell-Free Nucleic Acids 19%
32. Cholangiocarcinoma 19%
33. Nomograms 19%
34. Hepatocyte Growth Factor 18%
35. Genetic Heterogeneity 18%
36. Neuroendocrine Tumors 17%
37. Chromatin 17%
38. Docetaxel 17%
39. gemcitabine 17%
40. Drug Therapy 17%
41. DNA 17%
42. Histone Deacetylases 17%
43. Mucins 16%
44. Hydrogels 16%
45. Lung 16%
46. Chemoradiotherapy 16%
47. Microsatellite Repeats 16%
48. Rectal Neoplasms 16%
49. Histology 16%